{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:40Z","timestamp":1794047500009,"version":"4.8.0"},"reference-count":10,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>X-linked acrogigantism (X-LAG) is characterized by extreme tall stature from early childhood resulting from duplication of the GPR101 gene, in turn resulting in GH excess. Most cases present with pituitary tumors secreting GH and prolactin. Diffuse pituitary hyperplasia is uncommon and normal prolactin is rare. We present a girl with tall stature from 3 years of age; her height was +4.25 SD score at 5\u2005years, with no signs of syndromic disease. She had significant GH excess, serum IGF-1 4 times the upper limit of normal and normal circulating GHRH, with normal pituitary magnetic resonance imaging over 13\u2005years. No abnormalities were found in either the AIP or MEN1 genes. Treatment with somatostatin analogues and dopamine agonists showed minimal therapeutic benefit, but significant side effects. She tested positive for duplication of GPR101 6\u2005years after the initial diagnosis. She was then initiated on pegvisomant aged 12\u2005years, achieving prompt IGF-1 normalization and growth cessation. Aged 16.5\u2005years, she showed escape from IGF-1 control, and height velocity increased, but this responded well to a dose increase in pegvisomant, with reassuring long-term pediatric safety over 7\u2005years. Her final height is +2.9 SD score. Currently, life-long pegvisomant treatment is planned with genetic counselling regarding future offspring.<\/jats:p>","DOI":"10.1210\/jcemcr\/luad028","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T18:42:16Z","timestamp":1678992136000},"source":"Crossref","is-referenced-by-count":9,"title":["Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism"],"prefix":"10.1210","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3778-2945","authenticated-orcid":false,"given":"Christine P","family":"Burren","sequence":"first","affiliation":[{"name":"Department of Paediatric Endocrinology and Diabetes, Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust , Bristol BS1 3NU , UK"},{"name":"Bristol Medical School, Department of Translational Health Sciences, University of Bristol , Bristol BS8 1UD , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology, Noah's Ark Children's Hospital for Wales , Cardiff CF14 4XW , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Coxson","sequence":"additional","affiliation":[{"name":"Department Paediatrics, Royal United Hospital , Bath BA1 3NG , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-9432","authenticated-orcid":false,"given":"M\u00e1rta","family":"Korbonits","sequence":"additional","affiliation":[{"name":"Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London , London EC1M 6BQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"5777","key":"2023071208140478200_luad028-B1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1126\/science.1126100","article-title":"Pituitary adenoma predisposition caused by germline mutations in the AIP gene","volume":"312","author":"Vierimaa","year":"2006","journal-title":"Science"},{"issue":"25","key":"2023071208140478200_luad028-B2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","article-title":"Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation","volume":"371","author":"Trivellin","year":"2014","journal-title":"N Engl J Med"},{"key":"2023071208140478200_luad028-B3","volume-title":"GeneReviews","author":"Iacovazzo"},{"issue":"12","key":"2023071208140478200_luad028-B4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1159\/000512240","article-title":"A Chinese case of X-linked acrogigantism and systematic review","volume":"111","author":"Liang","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2023071208140478200_luad028-B5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11102-020-01105-4","article-title":"Genetics, clinical features and outcomes of non-syndromic pituitary gigantism: experience of a single center from Sao Paulo, Brazil","volume":"24","author":"Trarbach","year":"2021","journal-title":"Pituitary"},{"issue":"4","key":"2023071208140478200_luad028-B6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ajhg.2022.02.002","article-title":"Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism","volume":"109","author":"Franke","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"10","key":"2023071208140478200_luad028-B7","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1210\/jc.2019-00817","article-title":"Familial X-linked acrogigantism: postnatal outcomes and tumor pathology in a prenatally diagnosed infant and his mother","volume":"104","author":"Wise-Oringer","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023071208140478200_luad028-B8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40478-016-0328-1","article-title":"Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study","volume":"4","author":"Iacovazzo","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"2023071208140478200_luad028-B9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2023071208140478200_luad028-B10","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1210\/jc.2019-00432","article-title":"Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP mutation positive child","volume":"104","author":"Dutta","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/3\/luad028\/50858994\/luad028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/3\/luad028\/50858994\/luad028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T04:14:21Z","timestamp":1689135261000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luad028\/7198292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luad028","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,5]]},"article-number":"luad028"}}